Last checked at 8 Jun 2020 07:00
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
8 June 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Directorate Changes
Notice of results
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, today announces the following changes to its Board of Directors.
Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han, and Dr Yuelong Huang (all Non-Executive Directors of the Company), will step down from the Board and not seek re-election at the Company's upcoming Annual General Meeting ("AGM") which is expected to be held in July 2020. Once these Board changes become effective in July 2020, the Board will decrease from 12 members to eight members and will comprise of three executive directors and five non-executive directors.
The audited results for the year ended 31 December 2019 are expected to be announced on or around 29 June 2020. The annual report and accounts will be published shortly thereafter and posted to shareholders together with the notice of AGM.
Dr Mike Sinclair, Executive Chairman of Advanced Oncotherapy, commented:
"On behalf of the Board, I would like to thank Gabriel, Peter, Allen and Yuelong for their strategic counsel and insight to Advanced Oncotherapy over the years. As valued Board members, they have helped Advanced Oncotherapy to progress to a leading position as a technology disruptor in proton therapy, and we wish them all the best in their future endeavours."
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO | |
Allenby Capital Limited (Nomad & Broker) | |
Nick Athanas / Liz Kirchner / Nicholas Chambers | Tel: +44 (0) 20 3328 5656 |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.